Navigation Links
New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association
Date:3/2/2010

NASHVILLE, Tenn., March 2 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data from a recent study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating pain and fever in hospitalized burn patients will be presented at the 42nd Annual Meeting of the American Burn Association in Boston.

The new data will be displayed in a poster presentation on Wednesday, March 10, from 12:15 p.m. to 1:15 p.m. ET. The study, entitled "A Multi-Center, Randomized, Double-Blind Trial of Ibuprofen Injection for the Treatment of Fever and Pain in the Burn Patient," will be presented by Dr. John T. Promes, Associate Director for Surgical Education at Orlando Regional Medical Center, Assistant Professor of Surgery at the University of Central Florida College of Medicine, and Clinical Assistant Professor in the Department of Surgery at the Florida State University College of Medicine.

Concurrent with the presentation on March 10th, the poster will be available on Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm. Copies may also be obtained by contacting the Company at 615-255-0068.

The American Burn Association has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers who are dedicated to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. For more information, please visit www.ameriburn.org.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.

Back to top

RELATED LINKS
http://www.cumberlandpharma.com

'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Study, meta-analysis examine factors associated with death from heatstroke
5. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
6. Study says COPD testing is not measuring up
7. Preclinical study suggests organ-transplant drug may aid in lupus fight
8. Ability to cope with stress can increase good cholesterol in older white men, study finds
9. High alcohol consumption increases stroke risk, Tulane study says
10. Mailman School of Public Health study examines link between racial discrimination and substance use
11. Pitt study finds inequality in tobacco advertising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: